Trials / Completed
CompletedNCT03326856
ET-01 in Subjects With Lateral Canthal Lines
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Eirion Therapeutics Inc. · Industry
- Sex
- All
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Detailed description
This product is being tested for its ability to reduce lateral canthal lines, also known as Crow's Feet.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | botulinum toxin, Type A | topical liniment |
| BIOLOGICAL | Vehicle | Vehicle Formulation |
Timeline
- Start date
- 2017-10-25
- Primary completion
- 2018-06-11
- Completion
- 2018-11-14
- First posted
- 2017-10-31
- Last updated
- 2022-04-21
- Results posted
- 2021-09-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03326856. Inclusion in this directory is not an endorsement.